8-K filing — CERENOME, INC. (PSTV)
Filed: 2026-08-14 AccNo: 0001193125-26-352346 Size: 668 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Stocks · News reference
Plus Therapeutics Highlights Updated NCCN CNS Cancer Guidelines Reinforcing CSF Analysis In Leptomeningeal Metastases Care
Plus Therapeutics, Inc. (NASDAQ:PSTV) ("Plus" or the "Company"), today highlighted the recent update to the National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Plus Therapeutics’ CNSide Diagnostics Signs Regional Agreement With Medical Mutual Covering ~1.2M People Throughout Ohio And Kentucky, To Provide CNSide Cerebrospinal Fluid Tumor Cell Enumeration Assay
CNSide Diagnostics, LLC, a wholly-owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV) ("Plus" or the "Company"), announced today that it has signed a regional agreement with Medical Mutual
Plus Therapeutics Partners With Genomic Testing Cooperative To Integrate GTC's Next-Generation Sequencing Technology Into The CNSide Cerebrospinal Fluid Assay Platform
The collaboration is expected to enable comprehensive DNA and RNA profiling across hundreds of clinically relevant biomarkers from a single CSF specimen, extending CNSide from guideline-recognized CTC enumeration into